Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Behav Neurol ; 21(3): 137-43, 2009.
Article in English | MEDLINE | ID: mdl-19996510

ABSTRACT

Norepinephrine and dopamine are both believed to affect signal-to-noise in the cerebral cortex. Dopaminergic agents appear to modulate semantic networks during indirect semantic priming, but do not appear to affect problem solving dependent on access to semantic networks. Noradrenergic agents, though, do affect semantic network dependent problem solving. We wished to examine whether noradrenergic agents affect indirect semantic priming. Subjects attended three sessions: one each after propranolol (40 mg) (noradrenergic antagonist), ephedrine (25 mg) (noradrenergic agonist), and placebo. During each session, closely related, distantly related, and unrelated pairs were presented. Reaction times for a lexical decision task on the target words (second word in the pair) were recorded. No decrease in indirect semantic priming occurred with ephedrine. Furthermore, across all three drugs, a main effect of semantic relatedness was found, but no main effect of drug, and no drug/semantic relatedness interaction effect. These findings suggest that noradrenergic agents, with these drugs and at these doses, do not affect indirect semantic priming with the potency of dopaminergic drugs at the doses previously studied. In the context of this previous work, this suggests that more automatic processes such as priming and more controlled searches of the lexical and semantic networks such as problem solving may be mediated, at least in part, by distinct mechanisms with differing effects of pharmacological modulation.


Subject(s)
Brain/physiology , Linguistics , Mental Processes/physiology , Norepinephrine/metabolism , Receptors, Adrenergic/metabolism , Adrenergic Agonists/pharmacology , Adrenergic beta-Antagonists/pharmacology , Adult , Brain/drug effects , Cross-Over Studies , Double-Blind Method , Ephedrine/pharmacology , Female , Humans , Male , Mental Processes/drug effects , Neuropsychological Tests , Propranolol/pharmacology , Reaction Time , Young Adult
3.
Neurology ; 72(11): 987-91, 2009 Mar 17.
Article in English | MEDLINE | ID: mdl-19289738

ABSTRACT

OBJECTIVE: To determine the reaction of neurology practitioners to the Food and Drug Administration (FDA) alert concerning suicidality (suicidal ideation or behavior) and antiepileptic drugs. METHODS: We designed a 21-question survey asking about the participants' approach to suicidality and depression in patients with epilepsy (PWE), and their reaction to the FDA alert and its impact on their clinical practices. Participants (n = 780) were invited via e-mail to respond to a Zoomerang survey. Two reminders were sent to increase the response. RESULTS: The survey was completed by 175 participants (22%). Most were epilepsy specialists practicing in academic settings. Almost 62% did not use any scale to routinely screen for depression in PWE. For those who used a scale, the Beck Depression Inventory was the most used one. About 42% did not feel comfortable initiating treatment for depression. Although 98% warn about behavioral side effects when starting antiepileptic drugs, only 44% warn specifically about suicidal ideations or behavior. More than half were not aware of patients who attempted to commit suicide or who had committed suicide. The mean scores for the FDA alert clarity, appropriateness, and impact on clinical practice (on a scale from 1 to 10) were low, at 5.3, 4.1, and 3.6. Almost 46% did not feel the alert is going to change their practice. CONCLUSION: The Food and Drug Administration alert did not get a favorable score from the surveyed responders. Participants actively alert patients about behavioral side effects of antiepileptic drugs, but are not specific about suicide.


Subject(s)
Anticonvulsants/adverse effects , Depression/diagnosis , Depression/psychology , Epilepsy/psychology , Suicide/statistics & numerical data , Adverse Drug Reaction Reporting Systems , Anticonvulsants/therapeutic use , Data Collection , Epilepsy/complications , Epilepsy/drug therapy , Humans , Physicians , Psychiatric Status Rating Scales , United States , United States Food and Drug Administration
4.
Neurocase ; 14(4): 378-83, 2008.
Article in English | MEDLINE | ID: mdl-18766980

ABSTRACT

The noradrenergic system modulates performance on tasks dependent on semantic and associative network flexibility (NF) in individuals without neurodevelopmental diagnoses in experiments using a beta-adrenergic antagonist, propranolol. Some studies suggest drugs decreasing noradrenergic activity are beneficial in ASD. In individuals without neurodevelopmental diagnoses, propranolol is beneficial only for difficult NF-dependent problems. However, in populations with altered noradrenergic regulation, propranolol also benefits performance for simple problems. Due to decreased flexibility of access to networks in ASD, we wished to examine the effect of propranolol on NF in ASD. ASD subjects benefited from propranolol on simple anagrams, whereas control subjects were impaired by propranolol. Further study will be necessary to confirm this finding in a larger sample and to compare clinical response with cognitive response to propranolol.


Subject(s)
Adrenergic beta-Antagonists , Asperger Syndrome/drug therapy , Autistic Disorder/drug therapy , Problem Solving/drug effects , Propranolol , Adrenergic beta-Antagonists/pharmacology , Adrenergic beta-Antagonists/therapeutic use , Adult , Asperger Syndrome/physiopathology , Autistic Disorder/physiopathology , Behavior/drug effects , Child, Preschool , Double-Blind Method , Female , Hemodynamics/drug effects , Humans , Intelligence , Language , Male , Neuropsychological Tests , Placebos , Propranolol/pharmacology , Propranolol/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...